Rapibloc 300 mg, Pulver zur Herstellung einer Infusionslösung

7680686110014 CH-68611 Pulver
Rapibloc 300 mg, Pulver zur Herstellung einer Infusionslösung
Rapibloc 300 mg, Pulver zur Herstellung einer Infusionslösung
Rapibloc 300 mg, Pulver zur Herstellung einer Infusionslösung
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Pulver
Galenic group
Lösbar zur Einnahme

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
01/02/2023
Summary of Product Characteristics
Français
01/02/2023
Summary of Product Characteristics
Italien
01/02/2023

Detailed composition

Substance Quantity Type Category
(N/A)
300.0 MG Substance WIZUS
(N/A)
280.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HBESI

Authorization holder

OrPha Swiss GmbH

8700 Küsnacht ZH

Authorization information

Swissmedic authorization number
68611
Drug name
Rapibloc, Pulver zur Herstellung einer Infusionslösung
Galenic form
PULVI
ATC Code
C07AB14
Authorization status
Z
Dispensing category
B
First authorization
19/10/2022
Authorization expiration date
18/10/2027
IT Number
02.03.0.
Domain
Human medicine
Field of application
Hoch selektiver Beta-1-Adrenorezeptor-Antagonist

Package details

Description (FR)
RAPIBLOC subst sèche 300 mg flac
Description (DE)
RAPIBLOC Trockensub 300 mg Durchstf
Market launch
19/10/2022
Narcotic (BTM)
No